Ranok Therapeutics (hangzhou) Co., Ltd.
Clinical trials sponsored by Ranok Therapeutics (hangzhou) Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New targeted pill takes on Hard-to-Treat pancreatic cancer Results expected Nov 2026 (estimated)
- New drug targets Hard-to-Treat cancer mutation in early trial Results expected Dec 2026 (estimated)
- Healthy volunteers needed to test how food changes drug absorption Results expected Dec 2026 (estimated)
-
New targeted pill takes on Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis Phase 2 trial is testing an oral drug called RNK08954 in 60 people with metastatic pancreatic cancer that has a specific genetic change (KRAS G12D mutation). The drug is taken daily and aims to slow tumor growth. Researchers will measure how long the cancer stays under contr…
Phase 2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug targets Hard-to-Treat cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug, RNK08954, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to find a safe and effective dose and see if the drug can shrink tumors or slow their growth. About 152 adults who have already tried stan…
Phase 1/2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC